Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

September 30, 2025

Conditions
Colorectal CarcinomaGastric AdenocarcinomaGEJ AdenocarcinomaEsophageal AdenocarcinomaCholangiocarcinomaGallbladder Carcinoma
Interventions
DRUG

tucatinib

For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.

DRUG

trastuzumab

Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.

DRUG

oxaliplatin

85 mg/m\^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m\^2 given every 3 weeks.

DRUG

leucovorin

200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.

DRUG

fluorouracil

400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.

DRUG

capecitabine

1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.

DRUG

pembrolizumab

400 mg given by IV on day 1 of cycle 1, then every 6 weeks.

Trial Locations (28)

20016

Sibley Memorial Hospital, Washington D.C.

27710

Duke University Medical Center, Duke Cancer Center, Durham

Duke University Medical Center, Durham

44195

Cleveland Clinic Taussig Cancer Center Investigational Pharmacy, Cleveland

Cleveland Clinic, Cleveland

63031

Siteman Cancer Center - North County, Florissant

63108

Siteman Cancer Center, St Louis

63110

Barnes-Jewish Hospital, St Louis

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center - South County, St Louis

63141

Siteman Cancer Center - West County, Creve Coeur

63376

Siteman Cancer Center - St Peters, City of Saint Peters

80045

University of Colorado Denver CTO(CTRC), Aurora

University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora

University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora

80218

PCM Trials, Denver

85054

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic, Scottsdale

87131

University of New Mexico Comprehensive Cancer Center, Albuquerque

98109

Fred Hutchinson Cancer Center, Seattle

98195

University of Washington Medical Center, Seattle

464-8681

Aichi Cancer Center Hospital, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa-shi

216-8511

St. Marianna University Hospital, Kawasaki

541-8567

Osaka International Cancer Institute, Osaka

104-0045

National Cancer Center Hospital, Chuo-ku

135-8550

Cancer Institute Hospital of Japanese Foundation for Cancer Research., Koto-ku

All Listed Sponsors
lead

Seagen, a wholly owned subsidiary of Pfizer

INDUSTRY